January 2026
Serotonin
What January 2026's 22 new studies found, synthesized from the papers below. All Serotonin research →
The synthesis
Synthesized from 22 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Serotonin, 5-HT, serotonergic, 5-HT2A receptor, then ranked by relevance.
Research on serotonin in January 2026 focused heavily on psychedelic compounds, particularly psilocybin, with consistent evidence from clinical trials and reviews supporting rapid and sustained antidepressant effects, likely mediated by 5-HT2A receptor activation and neuroplasticity. Preclinical studies also identified mechanisms such as Gi signaling and long-term synaptic depression, while safety data showed no seizure liability for 5-MeO-DMT. However, most findings come from small samples, animal models, or narrative reviews, and durability beyond six months remains uncertain.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects 2026 | narrative review | Supports | Psilocybin-assisted therapy is associated with rapid antidepressant effects and durability signals, with convergent animal and human mechanistic findings supporting neuroplasticity as a contributor to sustained improvement. | |
| The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review 2026 | narrative review | Supports | Psilocybin-assisted therapy shows promising results with higher therapeutic efficacy compared to conventional treatments for depression, offering hope for sustained effects and minimal adverse effects. | |
| 5-Methoxy-N,N-Dimethyltryptamine: Functional Safety Pharmacology and Video-EEG Assessment of a Short-Acting Serotonergic Psychedelic in Beagle Canines. 2026 | preclinical animal study | 11 | No effect | Intranasal administration of 5-MeO-DMT did not induce seizures or epileptiform activity in a canine model sensitive to serotonergic drug-induced seizures. |
| Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling. 2026 | experimental study | Supports | 5-HT2AR-mediated non-canonical Gi signaling is essential for hallucinogenic effects, and a Gq-biased derivative, DOI-NBOMe, shows therapeutic effects in mice without hallucinogenic effects. | |
| Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N -Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure 2026 | rational design, synthesis, and evaluation of a focused library | Supports | Fluorinated carbamate derivatives of psilocin can reduce acute psilocin exposure and attenuate hallucinogenic-like effects while maintaining serotonergic activity and favorable pharmacokinetics. | |
| THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS 2026 | systematic review | Supports | Psychedelic-assisted therapy represents a transformative shift from chronic symptom management to rapid, episodic curative interventions, provided regulatory and ethical challenges are addressed. | |
| Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms 2026 | laboratory experiment | Supports | Psilocin induces a sex-independent, presynaptic long-term synaptic depression in the rat prelimbic cortex that is independent of 5-HT2A and metabotropic glutamate group 2 receptors, mediated by enhanced GABAergic tone, and fully blocked by a TrkB receptor antagonist. | |
| Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis 2026 | experimental study | 28 | Mixed | Chronic mild stress activates microglia and immune responses in the spinal cord despite psilocybin administration, as indicated by increased Arg1, TNF-α, and IL-10 levels. |
| Psilocybin rapidly, but not immediately, reverses reward learning deficits in a durable manner in an inflammatory rat model of depressive symptoms 2026 | animal study | Supports | Acute psilocybin (0.3 mg/kg) reverses impaired reward-induced biases within 24 hours, with effects enduring for at least 7 days in a rat model of depression. | |
| Effects of 5-HT 2A Receptor Activation on Oxycodone Demand after Short and Long Access Self-Administration in Male and Female Rats 2026 | preclinical experimental study | Mixed | DOI dose- and sex-dependently reduced oxycodone demand in rats, an effect driven mostly by the 5-HT2A receptor, but the receptor mediating these effects depended on the short- or long-access condition. | |
| An exploration of the relationships between the effects of psilocybin on behavior, 5-HT 2A receptor occupancy, and neuroplastic effects in mice 2026 | preclinical study | Supports | Psilocybin produces dose-dependent 5-HT₂A receptor occupancy and region-specific neuroplastic changes in the prefrontal cortex, with distinct behavioral effects associated with anxiolytic-like and antidepressant-like properties. | |
| Snapshot IP 1 Detection Following 5-HT 2 A Receptor Stimulation in the Mouse Brain 2026 | experimental study | Supports | The ex vivo platform measuring IP1 turnover in mouse frontal cortex distinguishes psychedelic from nonpsychedelic 5-HT2AR agonists, with DOI and LSD increasing IP1 but lisuride not, and MDMA increasing IP1 via serotonin release. | |
| The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors. 2026 | review | Unclear | DOI has been a key pharmacological tool for studying 5-HT2A and 5-HT2C receptors in over 1,200 publications, but its potential scheduling may restrict future research, prompting the need for alternative compounds. | |
| The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures 2026 | double-blinded placebo-controlled study | 24 | Supports | Psilocybin caused a rightward shift in the bisection point and increased the just noticeable difference, indicating subjective time slowing and decreased temporal precision. |
| Partydrogen im Überblick 2026 | review | Unclear | Party drugs encompass a broad spectrum of substances with diverse pharmacological mechanisms, and their use is associated with both acute and long-term risks that vary based on substance, use patterns, and contextual factors. | |
| Behavioral effects of psychedelic and non-psychedelic serotonin 2A receptor agonist drugs in pigs 2026 | preclinical experimental study | 26 | Mixed | At 60–70% cerebral 5-HT2AR occupancy, lisuride elicited more headshakes than psilocybin, DMT, or LSD in pigs, and the time course of headshakes corresponded to each drug's plasma pharmacokinetics. |
| LSD 5-HT2A receptor occupancy and global functional connectivity effects 2026 | pre-registered protocol | Supports | LSD occupies the serotonin 2A receptor and alters global functional connectivity in healthy humans. | |
| A Randomized Controlled Trial of Psilocybin for the Treatment of Obsessive-Compulsive Disorder 2026 | randomized placebo-controlled trial | Supports | Psilocybin led to a significant reduction in OCD symptoms, ranging from moderate improvement (23%) to complete remission (100%), with no severe side effects. | |
| Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity 2026 | experimental study | Mixed | All tested serotonergic psychedelics converge on inhibition of neurotransmission, though substance-specific effects on synaptic vesicle fusion, glutamate release, presynaptic calcium, and network activity were observed. | |
| Psychedelics and the quantum brain: a falsifiable hypothesis on Posner molecules and spin-dependent pharmacology. 2026 | theoretical or philosophical paper | Unclear | Proposes that classical serotonergic psychedelics may induce quantum coherence and entanglement in Posner molecules within neural tissue, potentially influencing pharmacological outcomes. | |
| The entactogen MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") disrupts helping behaviour while reinforcing electrophysiological indicators of potentially associated synaptic plasticity in male Sprague-Dawley rats. 2026 | experimental study | Mixed | MDMA suppressed helping behavior in rats at higher doses (5 mg/kg and 10 mg/kg) while enhancing neuroplasticity in brain regions linked to prosocial behavior. | |
| Allostatic Recalibration Theory (ART): Serotonergic Psychedelics Exert Transdiagnostic Therapeutic Effects by Recalibrating Allostasis to the Environment 2026 | theoretical or philosophical paper | Unclear | Proposes that the transdiagnostic therapeutic effects of psychedelics follow from allostatic recalibration, replacing entrenched pathological allostatic programs with updated programs tuned to the safe and supportive context of psychedelic therapy. |
Psilocybin-assisted therapy is associated with rapid antidepressant effects and durability signals, with convergent animal and human mechanistic findings supporting neuroplasticity as a contributor to sustained improvement.
narrative review
Psilocybin-assisted therapy shows promising results with higher therapeutic efficacy compared to conventional treatments for depression, offering hope for sustained effects and minimal adverse effects.
narrative review
Intranasal administration of 5-MeO-DMT did not induce seizures or epileptiform activity in a canine model sensitive to serotonergic drug-induced seizures.
preclinical animal study Sample size: 11
5-HT2AR-mediated non-canonical Gi signaling is essential for hallucinogenic effects, and a Gq-biased derivative, DOI-NBOMe, shows therapeutic effects in mice without hallucinogenic effects.
experimental study
Fluorinated carbamate derivatives of psilocin can reduce acute psilocin exposure and attenuate hallucinogenic-like effects while maintaining serotonergic activity and favorable pharmacokinetics.
rational design, synthesis, and evaluation of a focused library
Psychedelic-assisted therapy represents a transformative shift from chronic symptom management to rapid, episodic curative interventions, provided regulatory and ethical challenges are addressed.
systematic review
Psilocin induces a sex-independent, presynaptic long-term synaptic depression in the rat prelimbic cortex that is independent of 5-HT2A and metabotropic glutamate group 2 receptors, mediated by enhanced GABAergic tone, and fully blocked by a TrkB receptor antagonist.
laboratory experiment
Chronic mild stress activates microglia and immune responses in the spinal cord despite psilocybin administration, as indicated by increased Arg1, TNF-α, and IL-10 levels.
experimental study Sample size: 28
Acute psilocybin (0.3 mg/kg) reverses impaired reward-induced biases within 24 hours, with effects enduring for at least 7 days in a rat model of depression.
animal study
DOI dose- and sex-dependently reduced oxycodone demand in rats, an effect driven mostly by the 5-HT2A receptor, but the receptor mediating these effects depended on the short- or long-access condition.
preclinical experimental study
Psilocybin produces dose-dependent 5-HT₂A receptor occupancy and region-specific neuroplastic changes in the prefrontal cortex, with distinct behavioral effects associated with anxiolytic-like and antidepressant-like properties.
preclinical study
The ex vivo platform measuring IP1 turnover in mouse frontal cortex distinguishes psychedelic from nonpsychedelic 5-HT2AR agonists, with DOI and LSD increasing IP1 but lisuride not, and MDMA increasing IP1 via serotonin release.
experimental study
DOI has been a key pharmacological tool for studying 5-HT2A and 5-HT2C receptors in over 1,200 publications, but its potential scheduling may restrict future research, prompting the need for alternative compounds.
review
Psilocybin caused a rightward shift in the bisection point and increased the just noticeable difference, indicating subjective time slowing and decreased temporal precision.
double-blinded placebo-controlled study Sample size: 24
Party drugs encompass a broad spectrum of substances with diverse pharmacological mechanisms, and their use is associated with both acute and long-term risks that vary based on substance, use patterns, and contextual factors.
review
At 60–70% cerebral 5-HT2AR occupancy, lisuride elicited more headshakes than psilocybin, DMT, or LSD in pigs, and the time course of headshakes corresponded to each drug's plasma pharmacokinetics.
preclinical experimental study Sample size: 26
LSD occupies the serotonin 2A receptor and alters global functional connectivity in healthy humans.
pre-registered protocol
Psilocybin led to a significant reduction in OCD symptoms, ranging from moderate improvement (23%) to complete remission (100%), with no severe side effects.
randomized placebo-controlled trial
All tested serotonergic psychedelics converge on inhibition of neurotransmission, though substance-specific effects on synaptic vesicle fusion, glutamate release, presynaptic calcium, and network activity were observed.
experimental study
Proposes that classical serotonergic psychedelics may induce quantum coherence and entanglement in Posner molecules within neural tissue, potentially influencing pharmacological outcomes.
theoretical or philosophical paper
MDMA suppressed helping behavior in rats at higher doses (5 mg/kg and 10 mg/kg) while enhancing neuroplasticity in brain regions linked to prosocial behavior.
experimental study
Proposes that the transdiagnostic therapeutic effects of psychedelics follow from allostatic recalibration, replacing entrenched pathological allostatic programs with updated programs tuned to the safe and supportive context of psychedelic therapy.
theoretical or philosophical paper
Points of agreement
- Psilocybin and other serotonergic psychedelics show rapid and sustained antidepressant effects in clinical and preclinical models.
- 5-HT2A receptor activation is central to psychedelic effects and therapeutic mechanisms.
- Neuroplasticity is a key mechanism underlying sustained clinical improvement.
- Psychedelics can modulate synaptic function and induce long-term synaptic changes.
- Safety data indicate no seizure liability for 5-MeO-DMT in a canine model.
Conflicts
- Psilocybin's effects on microglial activation in the spinal cord were pro-inflammatory under chronic mild stress, contrasting with its anti-inflammatory properties reported elsewhere.
- MDMA suppressed helping behavior in rats at higher doses, conflicting with the notion that entactogens enhance prosocial behavior.
- Lisuride, a non-psychedelic 5-HT2A agonist, elicited more headshakes than psychedelics in pigs, challenging the assumption that headshake behavior is a reliable marker of psychedelic potential.
Gaps
- Durability of antidepressant effects beyond six months is not established.
- Most clinical evidence comes from small samples and open-label or narrative reviews; large-scale RCTs are lacking.
- Preclinical findings are mostly in animal models and may not translate to humans.
- The role of 5-HT2A receptor subtypes and biased signaling in therapeutic versus hallucinogenic effects requires further investigation.
- Long-term safety and abuse potential of novel compounds like DOI-NBOMe and fluorinated psilocin derivatives are unknown.
- The quantum brain hypothesis remains speculative and untested.